Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01819064 · ClinicalTrials.gov registry record · Phase 4
Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants
A Phase 4 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT01819064 is a Phase 4 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 60 participants.
The verdict
NCT01819064, a Phase 4 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
An infants heart rate is very important because it ensures that blood is pumped to all organs in the body. Heart rate may decrease during anesthesia and surgery, and this is why the anesthesiologist will often give a medication to prevent this from happening. The most common drug for this purpose is called atropine. The dose of most drugs given to babies is based upon the baby's weight, but some believe that the dose of atropine should not be less than 0.1mg. However there is no evidence to support this minimum dose. A larger dose of atropine may cause a very fast heart rate instead. Anesthesiologists routinely dose the atropine based upon the baby's weight without regard for a minimum dose. The purpose of the present study is to measure the heart rate after doses of atropine in neonates and infants who receive less than 0.1 mg.
Interventions
- DRUG Atropine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01819064
The ClinicalTrials.gov registry entry for NCT01819064 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atropine is the first listed.
NCT01819064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01819064 about?
NCT01819064 is a clinical study titled "Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants". An infants heart rate is very important because it ensures that blood is pumped to all organs in the body. Heart rate may decrease during anesthesia and surgery, and this is why the anesthesiologist will often give a medication to prevent this from happening. The most common drug for this purpose is...
What is the current status of trial NCT01819064?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2013-02. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01819064?
The interventions under investigation include: Atropine (DRUG).
Who is sponsoring clinical trial NCT01819064?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.